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Abstract 
 
Background 
Survival probability in children, adolescents and young adults with chronic myeloid leukemia 
(CML) has dramatically improved during recent years. Tyrosine kinase inhibitors (TKI), targeted 
drugs developed for patients with CML, were introduced in 2001 in England. We here quantify 
the trends in the “cure” proportion according to the year of diagnosis. 
Methods 
We included all children, adolescents and young patients with CML (0 to 24 years) diagnosed in 
England during 1980-2005. We fitted mixture cure models to estimate the “cure” proportion and 
the median survival time among the “uncured” patients according to the year of diagnosis, 
adjusted for age at diagnosis.  
Results 
The “cure” proportion increased dramatically between 1980 and 2005, from under 10% to over 
80%, while conversely, the median survival time of "uncured" patients decreased slightly 
between 1980 and 1999, with the trend from 2000 being uncertain. 
Conclusions 
The striking improvement of the “cure” fraction in young patients with CML since the early 
1980’s, is concomitant with improvement of treatment, especially the allogeneic hematopoietic 
stem cell transplant and, later, the introduction of TKI. The trends over the last years 2000-2005 
remain however uncertain and would benefit from further studies with more recent data and 
updated follow-up. 
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Introduction 1 
Chronic myeloid leukemia (CML) in children and young people is a rare disease, representing only 2 
2% of all leukemias in children diagnosed younger than 15 years and 9% of all leukemia in 3 
adolescents at age 15 to 19 years.1 The incidence is between 0.6 and 1.2 per million children per 4 
year, very low in infancy and rising with age.2 There are few clinical treatment guidelines for 5 
pediatric CML, so treatment is often derived from practice standards used in adult patients.1,3 6 
Natural course of disease is biphasic, it begins with a chronic phase (CP) with a median duration 7 
of four years, followed by acceleration phase lasting 6 to 18 months and finally transforming into 8 
resistant, rapidly fatal blast phase with a median survival of 3 to 9 months. Natural course of disease 9 
in children is comparable to that in adults.2,4 10 
The survival probability of children, adolescents and young adults diagnosed with CML showed a 11 
dramatic improvement during the last 30 years due to introduction of new drugs. Before 1980, 12 
CML was treated with “standard” chemotherapy. Busulfan, an alkylating agent active at the stem 13 
cell level, and hydroxyurea, an inhibitor of the ribonucleotide reductase, were used as palliative 14 
treatment to prolong CP.5,6 In the 1980s and 1990s, interferon alpha for chronic therapy and 15 
allogeneic hematopoietic stem-cell transplant (allo-HSCT) as curative option became mainstay of 16 
treatment.7 In 2001, tyrosine kinase inhibitor (TKI) imatinib was licensed as Glivec® in the United 17 
Kingdom (UK), in clinical practice TKI became available for patients older 18 years by 1999 and 18 
for younger patients by 2003. TKIs rapidly became the new gold standard treatment.1,8 In recent 19 
years, second-generation TKIs, such as dasatinib, nilotinib and others followed.2 TKI therapy 20 
results in not only a hematological response, but also a complete cytogenetic response followed by 21 
a status of minimal residual disease detectable only with highly sensitive methods like polymerase 22 
chain reaction.8 This is paralleled by great improvements in survival. However, a life-long therapy 23 
is required for most patients, while 10 to 15% of adult patients have successfully managed to stop 24 
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TKI treatment following the achievement of a deep and long-lasting molecular responses. This 25 
clearly demonstrated that a "functional" cure for CML is achievable.9 26 
Medical cure at the individual level is defined when the original neoplasm has been completely 27 
eradicated, and as pointed out by Zwaan and Sposto,10 “there are no residual sequelae attributable 28 
to having had the disease or being treated for it”. In this work, we investigated the population-29 
based level of “cure” (in contrast to the medical cure), i.e. it is defined at the group (and not 30 
individual) level of a cohort of patients. Therefore, we used the words “cured” and “uncured” in 31 
quotes, to make clear that this refers to statistical cure, which is computed and interpreted at the 32 
population-level. One important aspect of all cure models is that, for the cure proportion to be 33 
estimable, the survival curve must reach a plateau observed from the data.11 In such case, 34 
assumption of occurrence of cure is reasonable and using cure models would be adequate.12,13 As 35 
well as quantifying the proportion of patients "cured", cure models also allow estimating the 36 
median survival time of the "uncured" patients (i.e. the “fatal cases”), taking account of other 37 
factors14, such as the year of diagnosis, age at diagnosis, etc. Cure models have been developed 38 
and applied in different settings since the first publication by Boag.14-19 39 
Using cure models in all children, adolescents and young adults diagnosed with CML in England, 40 
we want to assess the trends in the probability to be “cured” (in a population-based meaning), with 41 
a specific interest in the impact of the new therapy with TKIs, used since 2001. We also investigate 42 
trends in the median survival time of the “uncured” patients. 43 
Material and Methods  44 
Data 45 
The source for the study dataset was UK National Cancer Registry.20 The subset analyzed were 46 
children (0 to 14 years), adolescents (15 to 19 years) and young adults (20 to 24 years) diagnosed 47 
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with CML in England between 1980 and 2005. Their vital status was assessed on the 31st December 48 
2015. So, we had a minimum of 10 years of potential follow-up for all patients. The time since 49 
diagnosis was used as the time scale, and for the analyses, we restricted the follow-up to the first 50 
15 years after diagnosis: patients alive at 15 years were censored. 51 
Descriptive analysis  52 
For descriptive purposes and for the univariable analysis, we categorized age at diagnosis in three 53 
age-groups (< 5 years, 5 to 14 years and 15 to 24 years), and the year of diagnosis in five periods 54 
(1980–1984, 1985–1989, 1990–1994, 1995–1999, 2000–2005).  55 
We plotted the survival probability according to calendar period of diagnosis using the non-56 
parametric Kaplan-Meier estimator. These plots allow for a visual assessment of the cure 57 
assumption (plateau).11  58 
Cure models 59 
Mixture cure models assume two subpopulations: a subpopulation considered as “cured” and a 60 
subpopulation of fatal cases, e.g. “uncured”.21 In these models, we express the probability to be 61 
alive at time t as the sum of (i) the probability to be cured and (ii) the probability to be uncured (i.e. 62 
one minus the probability to be cured) times the probability to be alive at time t for the uncured, 63 
which are the “fatal cases”, who died from any cause. Both the cure proportion and the survival 64 
probability of the fatal cases could depend on covariables such as year of diagnosis or age at 65 
diagnosis (multivariable model). From these expressions, we could derive the mortality rate, and 66 
thus the full log-likelihood (see technical details in the appendix). We applied the mixture cure 67 
models firstly in a univariable analysis on pre-defined subgroups, and secondly in a multivariable 68 
analysis. In all analysis, we assumed a Weibull distribution for the survival function of the 69 
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"uncured", and we used a logistic parametrization for the proportion of cured to constrain the cured 70 
fraction to fall in the range (0,1).12 The formulae are provided in the appendix. 71 
Univariable analyses 72 
For the univariable analyses, a mixture cure model without any covariable was fitted in each 73 
subgroup defined with the five periods of diagnosis defined above. We estimated the cure 74 
proportion as well as the parameters of the Weibull distribution for the fatal cases (i.e. the 75 
“uncured” group). The estimated parameters of the Weibull distribution for the fatal cases were 76 
used to calculate the median survival time of the “uncured”. We checked the quality of fit by 77 
comparing the non-parametric observed survival estimated for each period of diagnosis with the 78 
survival predicted using the estimated parameters from the fitted cure model. 79 
Multivariable analyses 80 
In the multivariable analyses, we assumed by default a non-linear effect of age at diagnosis both 81 
on the (logit of the) cure proportion and on the (log of the) scale parameter of the Weibull 82 
distribution: we used a quadratic regression spline with one knot located at 15 years. Regarding the 83 
effect of year of diagnosis, we fitted 4 different mixture cure models assuming either a linear or a 84 
non-linear effect of the year of diagnosis on either the (logit of the) cure proportion or on the (log 85 
of the) scale parameter of the survival distribution of the fatal cases, or on both. For the non-linear 86 
effect of year of diagnosis, we used a quadratic spline with one knot located at 1990 (the median 87 
of the observed distribution of year of diagnosis among the observed events). The mathematical 88 
details of the different models parametrizations are provided in the appendix. We used the Akaike 89 
Information Criterion (AIC) to select the final model. From the final model, we derived the 90 
temporal trends of the “cure” proportion and the median survival time of the “uncured” for specific 91 
8 
 
ages at diagnosis (6 months, and 5, 15 and 24 years). We derived Wald-type 95% confidence 92 
intervals, using the multivariate delta method22,23 for deriving the standard errors of the “cure” 93 
proportion and the median survival time of the “uncured”. To assess the fit of the final model, we 94 
compared the survival as predicted from the final cure model for a given age a and a year of 95 
diagnosis y to a non-parametric survival estimate obtained using the subgroups of patients aged 96 
between [a-2; a+2] and diagnosed in the period [y-2; y+2]. We also performed such comparison 97 
for the survival of the “uncured” only (see appendix for technical details). 98 
All the analyses were performed using the R software (version 3.4.1). 99 
Results 100 
Demographic characteristics 101 
Overall 538 patients aged 0 to 24 years were diagnosed with CML between 1980 and 2005 in 102 
England, and we observed 305 deaths (57%) (Table 1). Among the observed cases, 63% were in 103 
the age group 15-24 years old. The observed survival probabilities were extremely different 104 
according to the period of diagnosis, ranging from around 10% at 15 years for patients diagnosed 105 
between 1980 and 1984 compared to around 70% for patients diagnosed between 2000 and 2005 106 
(Figure 1). The survival for CML improved remarkably from 1995-1999 to 2000-2005.  107 
Mixture cure models 108 
Univariable analyses 109 
From the univariable analyses, we observed a dramatic increase of the “cure” proportion, from 9% 110 
in 1980-1984 (95% Confidence Interval [4%;22%]) to 71% (95% CI [62%; 79%]) in 2000-2005. 111 
The median survival time for the "uncured" group ranged between 1.52 years (95% CI [0·97; 2·06]) 112 
and 2.72 years (95% CI [1·61; 3·84]), without a clear temporal trend pattern (Table 2). Figure 2 113 
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shows a comparison of the trends of the “cure” proportion with the median survival time of the 114 
“uncured”. The trends showed an improvement of the “cure” proportion throughout 1980-2005. 115 
The pattern for the median survival time among the “uncured” was not so clear, with a decrease 116 
between 1985-1989 and 1995-1999, and a slight increase more recently (1995-1999 to 2000-2005). 117 
When assessing the fit of the univariable cure models, we obtained very comparable estimates for 118 
each period of diagnosis (Figure S1 in Appendix). 119 
Multivariable analyses 120 
The model with the lowest AIC (final model) was the model assuming a linear effect of the year of 121 
diagnosis on the survival of the “uncured” and a non-linear effect of the year of diagnosis on the 122 
“cure” proportion. From this model, we predicted the temporal trends of the “cure” proportion and 123 
the median survival time among the “uncured” for different ages at diagnosis: 6 months, 5 years, 124 
15 years and 24 years (Table 3 and Figure 3). From 1980 to 2005, we observed a slight decrease in 125 
median survival time of the “uncured” patients, going from 1 year in 1980 to half a year in 2005 126 
for infants diagnosed at 6 months, while it decreased from 4 to 2 years in patients aged 15 years 127 
old. Conversely, we observed a dramatic improvement from 1980 to 2005 of the “cure” proportion, 128 
rising to about 80% in 2005 for different ages at diagnosis (Table 3, Figure 3). When assessing the 129 
fit of the multivariable cure model, we observed good agreement between the 2 overall survival 130 
estimates (non-parametric vs. model-based) for each age/year combination (Figure S2 in 131 
Appendix), as well as between the 2 survival estimates of the “uncured” (Figure S3 in Appendix).  132 
Discussion 133 
Cancer registry data provide a unique opportunity to assess “cure” at the population level and over 134 
a long period. Here, we used cure models in pediatric and young adult patients with CML in 135 
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England, using data from the national population-based cancer registry to assess the temporal 136 
trends over a 26-year period of observation in the “cure” proportion. We had a potential follow-up 137 
time of at least 10 years for all patients diagnosed up to 2005. We also provided temporal trends of 138 
the median survival time for the “uncured” (the “fatal cases”). From 1980 to 2005, we estimated a 139 
spectacular increase in the proportion of patients “cure”, up to around 80% for patients diagnosed 140 
in 2005 for all age groups. The results about “cure” proportion were consistent in the univariable 141 
and the multivariable analyses. They were also in line with the results from the international 142 
registry for pediatric patients with CML.24  143 
For international comparison purposes, we did a PubMed search with terms ("cure models" AND 144 
leukemia AND children) and we found only two epidemiological studies, which however focused 145 
solely on childhood acute lymphoblastic leukemia.25,26 Other study in Great Britain assess “cure” 146 
proportion in leukemia for children diagnosed up to 2000, but focused on other more common 147 
subtypes, such as acute lymphoid and acute non-lymphoblastic leukemia.27 Another recent study 148 
from Trama et al. provided relative survival estimates and trends for adolescents and young adults 149 
over 2000-2007 using data gathered from 27 European Countries, but they did not present survival 150 
estimates for CML, or proportion of “cured”.28 Our results complement previous studies by 151 
quantifying the cure proportion and the median survival time of the uncured along with their trends 152 
over 1980-2005, on the whole England population of children, adolescents and young adults 153 
diagnosed with CML. 154 
We observed a slight discrepancy between the univariable and the multivariable analyses regarding 155 
the median survival time among the “uncured” over the period 2000-2005:the small increase in 156 
median survival time for “uncured” estimated from the univariable analyses for the period 2000-157 
2005 compared to 1995-1999 was not clearly confirmed by the multivariable analysis, which 158 
retained a slow decrease of the median survival time among the “uncured” throughout 1980-2005 159 
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with the final model. In the multivariable analysis, the model selection based on the AIC slightly 160 
favored the model with a simple linear effect of the year of diagnosis on the survival for the 161 
“uncured”. However, the AIC value of the model with a non-linear functional form for the year of 162 
diagnosis on the survival for the “uncured” was quite similar to the AIC value of the retained model 163 
(1912·64 vs. 1910·75 for the retained final model). The difference between the AIC values is less 164 
than 2, meaning than both models could have been selected as the closest model to the true 165 
generating model.29 When we used this more complicated model (the model with the non-linear 166 
effect of year of diagnosis on the “uncured” survival), we observed a slight increase in the median 167 
survival time among the “uncured” between 2000 and 2005 (Figure S4 in the appendix). Thus, we 168 
cannot conclude  with certainty on the trend of the median survival time among the “uncured” over 169 
the period 2000-2005; it will need to be confirmed in future studies with more recent data and 170 
updated follow-up. This will increase the power, and thus the ability of the model to better identify 171 
any potential increase in the median survival time among the “uncured”. From this more 172 
complicated model, the trends and the values of the “cure” proportion were however quite similar 173 
to the one provided by the final selected model, as was the trend of the median survival time among 174 
the “uncured” over the period 1980-2000 (Figure S4 in the appendix). Therefore, these consistent 175 
results reinforce the evidence of a (i) dramatic increase of the “cure” proportion from 1980 to 2005, 176 
and (ii) a slight decrease of the median survival time among the uncured from 1980 to 2000. To 177 
show the overall agreement between the 4 fitted models (with linear or non-linear effect of year of 178 
diagnosis on the cure proportion and/or on the survival of the “uncured), we provided a table in the 179 
appendix (Table S1) with the model-based estimates of the cure proportion and the median survival 180 
time of the “uncured” derived from each of the 4 fitted models, for 4 different values of age at 181 
diagnosis and year of diagnosis.  182 
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We used a Weibull distribution for survival of the "uncured" in the cure model. Other methods 183 
based on, for instance, the generalized modified Weibull distribution30 or flexible parametric 184 
models,31 could have provided more flexibility than the Weibull distribution. However, the visual 185 
checks comparing the non-parametric survival estimates to the survival predicted from the mixture 186 
cure models showed an adequate fit overall. We assumed an effect of variables only on the scale 187 
parameter of the Weibull distribution, as modelling the influence of covariables on the shape 188 
parameter is rarely necessary.12,32 This adequate fit was also confirmed by the comparison between 189 
(i) the model-based survival estimates for the “uncured” and (ii) the non-parametric observed 190 
survival estimates, once removed the component related to the “cure” (see the appendix for Figure 191 
S3, and for the mathematical details). 192 
It seems reasonable to assume that the large increase in the “cure” proportion depicted here between 193 
periods 1995-1999 and 2000-2005 is related to the introduction and implementation of TKI 194 
imatinib treatment in the National Health System of England, which occurred in 2001. Moreover, 195 
because the CML is a rare disease in children and young adults, it seems reasonable to assume that 196 
a substantial part of the incident cases studied here for England were included in adult clinical trials 197 
and thus had benefited from the treatment before its official introduction.33,34 This could partly 198 
explain the increase of the “cure” proportion before 2001. An additional explanation of the increase 199 
in the “cure” proportion before 2001 might be related to the implementation of interferon alpha 200 
and especially the use of allo-HSCT in the 1990s.35 It must be taken into consideration that allo-201 
HSCT from matched siblings became a frequent treatment option for those 25% of patients having 202 
a sibling donor in the early 1980’s. From 1990 onwards, unrelated donors became available for the 203 
majority (approximately 80%) of patients but the transplant related mortality was higher (more 204 
than 20%) than with sibling donors.36 The graphs in Figure 3 support the assumption that the broad 205 
introduction of unrelated allo-HSCT from the early 1990’s impacted the proportion of “cured” 206 
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patients, and the median survival time of the “uncured”. We can hypothesize that patients, who 207 
survived the therapy-related complications became long-term survivors, and the transplanted cases 208 
who died from transplant-related toxicities had shorter median survival time. Conversely, the 209 
apparent decrease in median survival time for “uncured” patients reported here could reflect a 210 
selective effect of the new treatment on patients with better prognosis. In other words, if a new 211 
treatment is selectively effective on patients with good prognosis, the “uncured” group will include 212 
mostly patients with more aggressive malignancy: this would lead to an apparent decrease in the 213 
median survival time of the “uncured” group, while the proportion of “cured” would increase. 214 
Another explanation for the decrease in the median survival time of the “uncured” throughout 215 
1980-2000 could be associated to the toxicity of the treatment, which would increase chances of 216 
being cured, but at the expense of a higher toxicity and shorter survival time for the “uncured”: 217 
patients treated with an intensive treatment with curative intent had a good chance of being cured, 218 
but treatment failure may shorten patient’s life (because of side effects). The uncertainty (explained 219 
in the beginning of the discussion) on the trend between 2000 and 2005 of the median survival time 220 
of the “uncured” calls for cautious interpretation on that specific period.  221 
Our results nonetheless support a remarkable change in the prognosis of young patients with CML, 222 
with a population-level “cure” proportion around 80% for patients diagnosed in 2000-2005. In the 223 
clinical and public health perspective however, this should be balanced with long-term side effects 224 
of life-long TKI therapy, such as growth restriction1, a particular concern in pre-pubertal children, 225 
diminished quality of life and secondary malignancies,37 especially in young patients, and further 226 
information and specific follow-up of patients are warranted.10 The uncertainty around the trend in 227 
median survival time for the “uncured” patients over 2000-2005 also warrants further consideration 228 
and exploration using more recent data. 229 
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Legends of figures and tables 
Figure 1 Overall survival estimates by period of diagnosis in children, adolescents and young 
adults diagnosed with chronic myeloid leukemia in England, 1980-2005  
Figure 2 Median survival time among “uncured” patients (in years) according to the proportion of 
“cure” for different periods of diagnosis, estimated with the univariable mixture cure model, in 
children, adolescents and young adults diagnosed with chronic myeloid leukemia in England, 
1980-2005 
Figure 3 Temporal trends of (i) the “cure” proportion (solid line) and (ii) the median survival 
time (in years) among the “uncured” (dashed line) with their corresponding 95% confidence 
intervals, estimated with the multivariable mixture cure model (final model, see method) in 
patients with chronic myeloid leukemia in England aged 6 months at diagnosis (A), 5 years (B), 
15 years (C) and 24 years (D), 1980-2005 
Table 1 Characteristics of patients (0-24 years) diagnosed between 1980 and 2005 with chronic 
myeloid leukemia in England by sex, age group and period of diagnosis 
Table 2 Results from the univariable mixture cure model: “cure” proportion and median survival 
time of the “uncured” (in years) with their 95% confidence intervals for each period of diagnosis, 
in children, adolescents and young adults diagnosed with chronic myeloid leukemia in England, 
1980-2005 
Table 3 Results from the multivariable mixture cure model (using the retained final model): 
“cure” proportion and median survival time of the “uncured” (in years) with their 95% 
confidence intervals for specific age at diagnosis and year of diagnosis, in children, adolescents 
and young adults diagnosed with chronic myeloid leukemia in England, 1980-2005 
 
